If 1% of patients account for 21% of total health care spending, why is there so little proof of ROI from giving them appropriate care?
Bundled payments, big data, and advances in personalized medicine will change the way primary care physicians and others practice
Provider groups put money into systems that heighten the focus on measuring performance
Qsymia and Belviq can slow the progression of diabetes, but side effects and retail cost of about $200 per month are obstacles to formulary placement
Emerging data show impressive results on glycemic control, but what about long-term results, safety, and high maintenance costs?
Consumers expect reasonable premiums and copayments but give health plans grief over a proven cost-control method. How soon we forget.
Management tactic borrowed from traditional pharmacy
Twenty-five years ago we had not even identified the virus that was neither type A nor type B. Now we have slowed its spread and can cure it, at considerable cost.
Nurse-managed health centers might ease PCP shortage
Eliminating Physicians' Wasted Time One Way to Address PCP Shortage
Just What Causes Health Care Inflation?
Colorectal Screening Called Inadequate
Our other journal
P&T Journal for November 2014
LETTER TO THE EDITOR
Medications for Parkinson’s Disease
The Changing Roles of P&T Committees
Epilepsy Management: Newer Agents, Unmet Needs, and Future Treatment Strategies
Modest Growth Seen in Epilepsy Market
European Society of Cardiology and Transcatheter Cardiovascular Therapeutics
“Generic: The Unbranding of Modern Medicine,” by Jeremy A. Greene, MD, PhD
Misadministration of IV Insulin Associated With Dose Measurement And Hyperkalemia Treatment
FDA’s Proposed 503B Draft Compounding Guidance Raises Concerns of All Kinds
New Drugs/Drug News
Pharmaceutical Approval Update
Riociguat (Adempas): a Novel Agent For the Treatment of Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension